Cargando…

Safety and Efficacy of Cyclosporine in the Treatment of Chronic Dry Eye

Dry-eye syndrome (DES) is a multifactorial disease affecting millions of individuals worldwide. Various factors, including age, hormonal status, genetics, sex, immune status, innervation status, nutrition, pathogens, and environmental stress, can alter the cellular and molecular structure or functio...

Descripción completa

Detalles Bibliográficos
Autor principal:	Schultz, Clyde
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Libertas Academica 2014
Materias:	Concise Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4076204/ https://www.ncbi.nlm.nih.gov/pubmed/25002818 http://dx.doi.org/10.4137/OED.S16067

Ejemplares similares

Treatment of chronic dry eye: focus on cyclosporine
por: Kymionis, George D, et al.
Publicado: (2008)

Efficacy and safety of using topical cyclosporine A for treatment of moderate to severe dry eye disease
por: Othman, Tageldin M., et al.
Publicado: (2018)

An Overview on Dry Eye Treatment: Approaches for Cyclosporin A Delivery
por: Yavuz, Burçin, et al.
Publicado: (2012)

Efficacy and safety of topical cyclosporine 0.1% in moderate-to-severe dry eye disease refractory to topical cyclosporine 0.05% regimen
por: Chan, Yuan-Hsi, et al.
Publicado: (2023)

One-Year Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Disease
por: Baudouin, Christophe, et al.
Publicado: (2017)

Topical Cyclosporine A for Treatment of Dry Eye Due to Chronic Mustard Gas Injury
por: Jadidi, Khosrow, et al.
Publicado: (2014)

Cyclosporine Amicellar delivery system for dry eyes
por: Kang, Han, et al.
Publicado: (2016)

A Randomized Study of the Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in Treatment of Moderate to Severe Dry Eye
por: Baudouin, Christophe, et al.
Publicado: (2017)

A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease
por: Wirta, David L., et al.
Publicado: (2019)

Efficacy and safety of HAT1 compared with calcipotriol in the treatment of patients with mild to moderate chronic plaque psoriasis: results from an open‐label randomized comparative pilot clinical study
por: Alex, P., et al.
Publicado: (2019)

Patient and physician perspectives on the use of cyclosporine ophthalmic emulsion 0.05% for the management of chronic dry eye
por: Deveney, Tatiana, et al.
Publicado: (2018)

A Review of the Mechanism of Action of Cyclosporine A: The Role of Cyclosporine A in Dry Eye Disease and Recent Formulation Developments
por: Periman, Laura M, et al.
Publicado: (2020)

Practical guidance for the use of cyclosporine ophthalmic solutions in the management of dry eye disease
por: de Oliveira, Rodrigo Carlos, et al.
Publicado: (2019)

Endpoints and New Options for Treatment of Chronic Hepatitis D
por: Lok, Anna S., et al.
Publicado: (2021)

Efficacy of Topical Cyclosporine Nanoemulsion 0.05% Compared with Topical Cyclosporine Emulsion 0.05% and Diquafosol 3% in Dry Eye
por: Park, Chang Hyun, et al.
Publicado: (2019)

Characteristics of structures and lesions of the eye in laboratory animals used in toxicity studies
por: Shibuya, Kazumoto, et al.
Publicado: (2015)

Cyclosporine (0.05%) Combined with Diclofenac Sodium Eye Drops for the Treatment of Dry Eye Disease
por: Bai, Run, et al.
Publicado: (2022)

Gatifloxacin Ophthalmic Solution for Treatment of Bacterial Conjunctivitis: Safety, Efficacy and Patient Perspective
por: Schultz, Clyde
Publicado: (2012)

Once-Daily Cyclosporine-A-MiDROPS for Treatment of Dry Eye Disease
por: Coursey, Terry G, et al.
Publicado: (2018)

Efficacy of topical cyclosporine 0.05% and osmoprotective lubricating eye drops in treating dry eye disease and inflammation
por: Mullick, Ritika, et al.
Publicado: (2021)

The Effects of Fisetin on Cyclosporine-Treated Dry Eye Disease in Dogs
por: Krajčíková, Kristína, et al.
Publicado: (2023)

Efficacy and safety of anakinra for undifferentiated autoinflammatory diseases in children: a retrospective case review
por: Garg, Suchika, et al.
Publicado: (2019)

Efficacy and safety of ixekizumab treatment in Japanese patients with moderate‐to‐severe plaque psoriasis: Subgroup analysis of a placebo‐controlled, phase 3 study (UNCOVER‐1)
por: Imafuku, Shinichi, et al.
Publicado: (2017)

Dry Eye Treatment with Topical Cyclosporine 0.1% in Chondroitin Sulfate Ophthalmic Emulsion
por: Matossian, Cynthia, et al.
Publicado: (2021)

Comparison of matrix metallopeptidase-9 expression following cyclosporine and diquafosol treatment in dry eye
por: So, Ha Rim, et al.
Publicado: (2023)

Practical approaches for evaluating adrenal toxicity in nonclinical safety assessment
por: Inomata, Akira, et al.
Publicado: (2015)

Real-World Effectiveness, Tolerability and Safety of Cyclosporine A 0.1% Cationic Emulsion in Severe Keratitis and Dry Eye Treatment
por: Geerling, Gerd, et al.
Publicado: (2022)

Efficacy and Safety of Intravenous Golimumab in Patients With Ankylosing Spondylitis and Complete Spinal Ankylosis: Results Through Week 52 of the GO-ALIVE Study
por: Deodhar, Atul, et al.
Publicado: (2022)

Assessment of the efficacy of 0.1% cyclosporine A cationic emulsion in the treatment of dry eye disease during COVID-19 pandemic
por: Stopyra, Wiktor
Publicado: (2023)

Health claims database study of cyclosporine ophthalmic emulsion treatment patterns in dry eye patients
por: Stonecipher, Karl G, et al.
Publicado: (2013)

Comparison of topical cyclosporine alone and topical loteprednol with cyclosporine in moderate dry eye in Indian population: A prospective study
por: Singla, Shaveta, et al.
Publicado: (2019)

Cognitive efficacy and neural mechanisms of music‐based neurological rehabilitation for traumatic brain injury
por: Martínez‐Molina, Noelia, et al.
Publicado: (2022)

Factors Influencing the Efficacy of Umbilical Cord Blood-Derived Cell Therapy for Perinatal Brain Injury
por: Purcell, Elisha, et al.
Publicado: (2023)

Management of COVID-19 patients with chronic liver diseases and liver transplants
por: Hu, Xinyu, et al.
Publicado: (2022)

The Association Between Periodontal Disease and Chronic Migraine: A Systematic Review
por: Mohammed, Marwan Mansoor Ali, et al.
Publicado: (2023)

The Effect of Topical Cyclosporine 0.05% on Dry Eye after Cataract Surgery
por: Chung, Yeon Woong, et al.
Publicado: (2013)

Efficacy and Safety of a Water-Free Topical Cyclosporine, 0.1%, Solution for the Treatment of Moderate to Severe Dry Eye Disease: The ESSENCE-2 Randomized Clinical Trial
por: Akpek, Esen K., et al.
Publicado: (2023)

A Real-World Analysis of Relapse Rate and Efficacy of a Restricted Monthly Dose of Omalizumab in Recalcitrant Chronic Spontaneous Urticaria in India
por: Sardana, Kabir, et al.
Publicado: (2020)

Efficacy of Baricitinib in the Treatment of Chilblains Associated With Aicardi‐Goutières Syndrome, a Type I Interferonopathy
por: Meesilpavikkai, Kornvalee, et al.
Publicado: (2019)

The Role of Lung Resident Mesenchymal Stromal Cells in the Pathogenesis and Repair of Chronic Lung Disease
por: Doherty, Declan F, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8b3sgdemoopqp976hk6pfsopmn